Rational Pharmacotherapy in Cardiology

Advanced search


Full Text:


Advanced age is the most important and independent risk factor for the development of atrial fibrillation (AF). The proportion of patients with AF at the age of 65-85 years reaches 70%, and average age of patients with AF is 75 years. Antithrombotic therapy of AF in the elderly is challenging for several reasons. On the one hand, elderly patients are at an increased risk of systemic embolism and stroke and fatal outcomes of stroke are higher in the elderly compared with these in the younger patients. On the other hand, elderlies are at an increased risk of bleeding. In addition, they have important comorbidities and are treated with drugs that can interact with antithrombotic agents. The article discusses tools used to assess risks of thromboembolic and hemorrhagic complications and general approaches to antithrombotic treatment of elderly patients.

About the Authors

E. A. Ushkalova
People's Friendship University of Russia
Russian Federation

Elena A. Ushkalova - MD, PhD, Professor, Chair of General and Clinical Pharmacology 

Miklukho-Maklaya ul. 6,Moscow, 117198 

S. K. Zyryanov
People's Friendship University of Russia
Russian Federation

Sergei K. Zyryanov - MD, PhD, Professor, Head of Chair of General and Clinical Pharmacology 

Miklukho-Maklaya ul. 6,Moscow, 117198 

E. V. Dumchenko
People's Friendship University of Russia
Russian Federation

Ekaterina V. Dumchenko - MD, PhD Student, Chair of General and Clinical Pharmacology 

Miklukho-Maklaya ul. 6,Moscow, 117198 


1. Camm A.J., Kirchhof P., Lip G.Y.H., et al. Guidelines for the management of atrial fibrillation. The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC), Developed with the special contribution of the European Heart Rhythm Association (EHRA) Eur Heart J. 2010;31:2369-429.

2. Hanon O., Assayag P., Belmin J., et al. Expert consensus of the French society of geriatrics and gerontology and the French society of cardiology on the management of atrial fibrillation in elderly people. Geriatr Psychol Neuropsychiatr Vieil. 2013;11(2):117-43.

3. Kirchhof P., Auricchio A., Bax J., et al. Outcome parameters for trials in atrial fibrillation: recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork and the European Heart Rhythm Association. Europace. 2007;9:1006—23.

4. Kannel W.B., Wolf P.A., Benjamin E.J., Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol. 1998;82:2N-9N.

5. Chugh S.S., Havmoeller R., Narayanan K., et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129(8):837-47.

6. Amin A., Houmsse A., Ishola A., et al. The current approach of atrial fibrillation management. Avicenna J Med. 2016; 6(1): 8-16.

7. Kistler P., Sanders P., Fynn S., et al. Electrophysiologic and electroanatomic changes in the human atrium associated with age. J Am Coll Cardiol. 2004;44:109-16.

8. Heeringa J., van der Kuip D.A., Hofman A., et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J. 2006;27:949-95.

9. Lloyd-Jones D.M., Wang T.J., Leip E.P., et al. Lifetime risk for. development of atrial fibrillation: the Framingham Heart Study. Circulation. 2004;110:1042-6.

10. Camm A.J., Savelieva I., Potpara T., et al. The changing circumstance of atrial fibrillation - progress towards precision medicine. J Intern Med. 2016;279(5):412-27.

11. Kolbin A.S., Tatarsky B.A.. Biserova I.N., et al. Socio-economic burden of atrial fibrillation in the Russian Federation. Klinicheskaya Farmakologiya i Terapiya. 2010; 19 (4): 17-22. (In Russ.) [Колбин А.С., Татарский, Б.А. Бисерова И.Н., и др. Социально-экономическое бремя мерцательной аритмии в Российской Федерации. Клиническая Фармакология и Терапия. 2010;19(4):17-22].

12. Hakim F.A., Shen W.K. Atrial fibrillation in the elderly: a review. Future Cardiol. 2014;10(6):745-58.

13. Kazemian P., Oudit G., Jugdutt B.I. Atrial fibrillation and heart failure in the elderly, Heart Fail Rev. 2012;17(4-5):597-613.

14. Camm A.J., Lip G.Y., De Caterina R., et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC. Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33(21):2719-4.

15. Pozzoli M., Cioffi G., Traversi E., et al. Predictors of primary atrial fibrillation and concomitant clinical and hemodynamic changes in patients with chronic heart failure: a prospective study in 344 patients with baseline sinus rhythm. J Am Coll Cardiol. 1998;32:197-204.

16. De Ferrari G.M., Klersy C., Ferrero P., et al. Atrial fibrillation in heart failure patients: Prevalence in daily practice and effect on the severity of symptoms. Data from the ALPHA study registry. Eur J Heart Fail. 2007;9:502-9.

17. Deedwania P.C., Lardizabal J.A. Atrial fibrillation in heart failure: A comprehensive review. Am J Med. 2010;123:198-204.

18. Ferreira C., ProvidРncia R., Ferreira M.J., GonНalves L.M. Atrial Fibrillation and Non-cardiovascular Diseases: A Systematic Review. Arq Bras Cardiol. 2015;105(5):519-26.

19. Boriani G., Pettorelli D. Atrial fibrillation burden and atrial fibrillation type: Clinical significance and impact on the risk of stroke and decision making for long-term anticoagulation. Vascul Pharmacol. 2016;83:26-35.

20. Rienstra M., Lubitz S.A., Mahida S., et al. Symptoms and Functional Status of Patients with Atrial Fibrillation: State-of-the-Art and Future Research Opportunities Circulation. 2012;125(23):2933-43.

21. Reiffel J.A. Atrial fibrillation and stroke: epidemiology. Am J Med. 2014;127(4):e15-6.

22. Wasmer K., Eckardt L. Management of atrial fibrillation around the world: a comparison of current ACCF/AHA/HRS, CCS, and ESC guidelines. Europace. 2011;13(10):1368-74.

23. Friberg L., Benson L., Lip G.Y. Balancing stroke and bleeding risks in patients with atrial fibrillation and renal failure: the Swedish Atrial Fibrillation Cohort study. Eur Heart J. 2015;36(5):297-306.

24. Marinigh R., Lip G.Y., Fiotti N., et al (2010). Age as a risk factor for stroke in atrial fibrillation patients. Heart Fail Rev. 2012;17:597-613.

25. Stroke Risk in Atrial Fibrillation Working G. Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology. 2007;69(6):546-54.

26. Kilickap M., Bosch J., Eikelboom J.W., Hart R.G. Antithrombotic treatments for stroke prevention in elderly patients with non-valvular atrial fibrillation: Drugs and doses. Can J Cardiol. 2016;32(9): 1108-16.

27. Olesen J.B., Fauchier L., Lane D.A., et al. Risk factors for stroke and thromboembolism in relation to age among patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project. Chest. 2012;141(1):147-53.

28. Wolf P.A., Abbott R.D., Kannel W.B. Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke. 1991;22:983-8.

29. WКndell P.E., Carlsson A.C., Sundquist J., et al. Pharmacotherapy and mortality in atrial fibrillation-a cohort of men and women 75 years or older in Sweden. Age Ageing. 2015;44(2):232-8.

30. ProvidРncia R., Marijon E., Boveda S., et al. Meta-analysis of the influence of chronic kidney disease on the risk of thromboembolism among patients with nonvalvular atrial fibrillation. Am J Cardiol. 2014;114(4):646-53.

31. Piccini J.P., Stevens S.R., Chang Y., et al. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts. Circulation. 2013;127(2):224-32.

32. Olesen J.B., Lip G.Y., Kamper A.L., et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med. 2012;367(7):625-35.

33. Xu D., Murakoshi N., Sairenchi T., et al. Anemia and reduced kidney function as risk factors for new onset of atrialfibrillation (from the Ibaraki Prefectural Health Study). Am J Cardiol. 2015;115(3):328-33.

34. Westenbrink B.D., Alings M., Connolly S.J., et al. Anemia predicts thromboembolic events, bleeding complicationsand mortality in patients with atrial fibrillation: insights from the RE-LY trial. J Thromb Haemost. 2015;13(5):699-707.

35. FernЗndez S.C., Formiga F., Camafort M. Antithrombotic treatment in elderly patients with atrial fibrillation: a practical approach. BMC Cardiovascular Disorders. 2015;15:143.

36. Sanders N.A., Ganguly J.A., Jetter T.L., et al. Atrial fibrillation: an independent risk factor for nonaccidental falls in older patients. Pacing Clin Electrophysiol. 2012;35:973-9.

37. Kundu A., Sardar P., Chatterjee S., et al. Minimizing the Risk of Bleeding with NOACs in the Elderly. Drugs Aging. 2016;33(7):491-500.

38. Udompanich S., Lip G.Y., Apostolakis S., Lane D.A. Atrial fibrillation as a risk factor for cognitive impairment: a semi-systematic review. QJM. 2013;106(9):795-802.

39. Edholm K., Ragle N., Rondina M.T. Anti-Thrombotic Management of Atrial Fibrillation in the Elderly. Med Clin North Am. 2015;99(2):417-30.

40. Karamichalakis N., Letsas K.P., Vlachos K., et al. Managing atrial fibrillation in the very elderly patient: challenges and solutions. Vasc Health Risk Manag. 2015;11:555-62.

41. Zhu W.G., Xiong Q.M., Hong K. Meta-analysis of CHADS2 versus CHA2DS2-VASc for predicting stroke and thromboembolism in atrial fibrillation patients independent of anticoagulation. Tex Heart Inst J. 2015;42(1):6-15.

42. Esteve-Pastor M.A., MarТn F., Bertomeu-Martinez V., et al. Do physicians correctly calculate thromboembolic risk scores? A comparison of concordance between manual and computer-based calculation of CHADS2 and CHA2DS2 -VASc scores. Intern Med J. 2016;46(5):583-9.

43. Xing Y., Ma Q., Ma X., et al. CHADS2 score has a better predictive value than CHA2DS2-VASc score in elderly patients with atrial fibrillation. Clin Interv Aging. 2016;11:941-6.

44. van den Ham H.A., Klungel O.H., Singer D.E., et al. Comparative Performance of ATRIA, CHADS2, and CHA2DS2-VASc Risk Scores Predicting Stroke in Patients With Atrial Fibrillation: Results From a National Primary Care Database. J Am Coll Cardiol. 2015;66(17):1851.

45. Aspberg S., Chang Y., Atterman A., et al. Comparison of the ATRIA, CHADS2, and CHA2DS2-VASc stroke risk scores in predicting ischaemic stroke in a large Swedish cohort of patients with atrial fibrillation. Eur Heart J. 2016;37(42):3203-3210.

46. Manning W.J., Singer D.E., Lip G.Y.H. Atrial fibrillation: Anticoagulant therapy to prevent embolization. UpToDate. Jul 06, 2016. Available at: Checked by: April 20, 2017.

47. Fauchier L., Chaize G., Gaudin A.F., et al. Predictive ability of HAS-BLED, HEMORR2HAGES, and ATRIA bleeding risk scores in patients with atrial fibrillation. A French nationwide cross-sectional study. Int J Cardiol. 2016;217:85-91.

48. Ioannou A., Metaxa S., Kassianos G., Missouris C.G. Anticoagulation for the prevention of stroke in non-valvular AF in general practice: room for improvement. Drugs Context. 2016;5:212295.

49. Olesen J.B., Lip G.Y., Lindhardsen J., et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: a net clinical benefit analysis using a ‘real world’ nationwide cohort study. Thromb Haemost. 2011;106:739-49.

50. Fang M.C., Go A.S., Chang Y., et al. Death and disability from warfarin-associated intracranial and extracranial hemorrhages. The American journal of medicine. 2007;120(8):700-5.

51. Fang M.C., Go A.S., Chang Y., et al. Thirty-day mortality after ischemic stroke and intracranial hemorrhage in patients with atrial fibrillation on and off anticoagulants. Stroke. 2012;43(7):1795-9.

52. Jones C., Pollit V., Fitzmaurice D., et al. The management of atrial fibrillation: summary of updated NICE guidance. BMJ. 2014;348:g3655.

53. January C.T., Wann L.S., Alpert J.S., et al. AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation. 2014;130(23):2071104.

54. Skanes A.C., Healey J.S., Cairns J.A., et al. Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. The Canadian Journal of Cardiology. 2012;28(2):125-36.

55. All-Russian scientific society of specialists in clinical electrophysiology, arrhythmology and pacemaking, Russian Cardiology Society, Association of Cardiovascular Surgeons. Diagnosis and treatment of atrial fibrillation. Russian guidelines. Available at: Checked by April 20, 2017. (In Russ.) [Всероссийское научное общество специалистов по клинической электрофизиологии, аритмологии и кардиостимуляции, Российскаое кардиологическое общество, Ассоциация сердечно-сосудистых хирургов. Диагностика и лечение фибрилляции предсердий. Российские рекомендации. Доступно на: Проверено 20.04.2017].

56. Fauchier L., Clementy N., Bisson A., et al. Should Atrial Fibrillation Patients With Only 1 NongenderRelated CHA2DS2-VASc Risk Factor Be Anticoagulated? Stroke. 2016;47(7):1831.

57. Saliba W. Non-vitamin K antagonist oral anticoagulants: new choices for patient management in atrial fibrillation. .Am J Cardiovasc Drugs. 2015;15(5):323-35.

58. Olesen J.B., Lip G.Y., Hansen M.L., et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ. 2011;342:d124.

59. Friberg L., Rosenqvist M., Lip G.Y. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J. 2012;33(12):1500-10.

60. Singer D.E., Chang Y., Borowsky L.H., et al. A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: the ATRIA study stroke risk score. Journal of the American Heart Association. 2013; 2(3):e000250.

61. Pugh D., Pugh J., Mead G.E. Attitudes of physicians regarding anticoagulation for atrial fibrillation: a systematic review. Age and Ageing. 2011;40(6):675-83.

62. Annoni G., Mazzola P. Real-world characteristics of hospitalized frail elderly patients with atrial fibrillation: can we improve the current prescription of anticoagulants? J Geriatr Cardiol. 2016;13(3):22632.

63. van Walraven C., Hart R.G., Connolly S., et al. Effect of age on stroke prevention therapy in patients with atrial fibrillation: the atrial fibrillation investigators. Stroke. 2009;40(4):1410-6.

64. Steinberg B.A., Greiner M.A., Hammill B.G., et al. Contraindications to anticoagulation therapy and eligibility for novel anticoagulants in older patients with atrial fibrillation. Cardiovasc Ther. 2015;33(4):177-83.

65. Chatterjee S., Sardar P., Giri J.S., et al. Treatment discontinuations with new oral agents for long-term anticoagulation: insights from a meta-analysis of 18 randomized trials including 101,801patients. Mayo Clin Proc. 2014;89(7):896-907.

66. Hohnloser S.H., Eikelboom J.W. The hazards of interrupting anticoagulation therapy in atrial fibrillation. Eur Heart J. 2012;33(15):1864-6.

67. Raunse J., Selmer C., Olesen J.B., et al. Increased short-term risk of thrombo-embolism or death after interruption of warfarin treatment in patients with atrial fibrillation. Eur Heart J. 2012;33(15):188692.

For citation:

Ushkalova E.A., Zyryanov S.K., Dumchenko E.V. APPROACHES TO ANTITHROMBOTIC THERAPY IN ELDERLY PATIENTS WITH ATRIAL FIBRILLATION. Rational Pharmacotherapy in Cardiology. 2017;13(2):275-283. (In Russ.)

Views: 267

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)